Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.

Saved in:
Bibliographic Details
Title: Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Authors: Janssen JJWM; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands. j.janssen@amsterdamumc.nl., Löwenberg B; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Manz M; USZ Zürich, Zürich, Switzerland.; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam University Medical Centers, loc. AMC, Amsterdam, The Netherlands., Westerweel PE; Albert Schweitzer Hospital, Dordrecht, The Netherlands., Klein SK; Department of Hematology, University Medical Center, Groningen, The Netherlands., Fehr M; Kantonsspital St. Gallen, St. Gallen, Switzerland., Sinnige HAM; Jeroen Bosch Hospital, Den Bosch, The Netherlands., Efthymiou A; HFR, Fribourg, Switzerland., Legdeur MCJC; Medisch Spectrum Twente, Enschede, The Netherlands., Pabst T; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Department of Medical Oncology, University Hospital Inselspital and University of Bern, Bern, Switzerland., Gregor M; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; KSL, Luzern, Switzerland., van der Poel MWM; Dept. of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Deeren D; AZ Delta, Roeselare, Belgium., Tick LW; Maxima Medical Center, Eindhoven, The Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Obbergh F; Hospital Saint Paul Jolimont, Haine, Belgium., Boersma RS; Amphia Hospital, Breda, The Netherlands., de Weerdt O; Antonius Hospital, Nieuwegein, The Netherlands., Chalandon Y; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland., Heim D; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; University Hospital, Basel, Switzerland., Spertini O; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland., van Sluis G; Isala Clinics, Zwolle, The Netherlands., Graux C; Mont Godinne, Yvoir, Belgium., Stüssi G; SAKK Swiss Clinical Cancer Research Group, Amsterdam, The Netherlands.; IOSI, Belinzona, Switzerland., van Norden Y; Hovon Data Center, Erasmus Medical Center, Rotterdam, The Netherlands., Ossenkoppele GJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, loc. VUmc, Amsterdam, The Netherlands.
Source: Leukemia [Leukemia] 2022 Sep; Vol. 36 (9), pp. 2189-2195. Date of Electronic Publication: 2022 Jul 22.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-022-01657-3